Cas:60511-85-5 Indolo[2,3-a]carbazole manufacturer & supplier

Chemical Name:Indolo[2,3-a]carbazole

CAS.NO:60511-85-5

Synonyms:11,12-Dihydroindolo[2,3-a]carbazole;Indolo[2,3-a]carbazole, 11,12-dihydro-;indolo[2,3-a]carbazole

Molecular Formula:C₁₈H₁₂N₂

Molecular Weight:256.301

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:569.8±23.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.924

PSA:31.58000

Exact Mass:256.100037

LogP:5.22

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 11,12-Dihydroindolo[2,3-a]carbazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,indolo[2,3-a]carbazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,11,12-Dihydroindolo[2,3-a]carbazole Use and application,11,12-Dihydroindolo[2,3-a]carbazole technical grade,usp/ep/jp grade.

Related News: The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. Indolo[2,3-a]carbazole manufacturer The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it. Indolo[2,3-a]carbazole supplier No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. Indolo[2,3-a]carbazole vendor The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. Indolo[2,3-a]carbazole factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.